Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches-Reference-Cited by-同舟云学术

Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches

Published:2023-08-02 Issue:8 Volume:36 Page:1427-1438
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Qin Xuan¹^ORCID,Wang Yong¹,MacKenzie Kevin R.¹²³,Hakenjos John M.¹,Chen Si⁴,Khalil Saleh M.¹,Jung Sung Yun⁵^ORCID,Young Damian W.¹³,Guo Lei⁴,Li Feng¹²³^ORCID

Affiliation:

1. Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas 77030, United States

2. NMR and Drug Metabolism Core, Advanced Technology Cores, Baylor College of Medicine, Houston, Texas 77030, United States

3. Department of Pharmacology & Chemical Biology, Baylor College of Medicine, Houston, Texas 77030, United States

4. Division of Biochemical Toxicology, National Center for Toxicological Research/U.S. Food and Drug Administration (FDA), Jefferson, Arkansas 72079, United States

5. Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, United States

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Bill and Melinda Gates Foundation

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Publisher

American Chemical Society (ACS)

Subject

Toxicology,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.3c00164

Reference27 articles.